According to Future Market Insights (FMI), the oxytocic pharmaceuticals market is likely to generate USD 114.58 million in revenue in 2023. The oxytocic pharmaceuticals industry is anticipated to thrive at a 7.8% CAGR from 2023 to 2033, reaching USD 242.83 million by 2033.
Due to the quick improvements in maternity care, expanding government programs, and rising rates of elective caesareans, growth estimates for Europe remain encouraging. With 31% of the region's oxytocic drug sales, Germany may hold a significant market share in Europe.
The primary factors fuelling market expansion are a rise in the tendency to give birth in hospitals rather than at home and an uptick in caesarian deliveries. The oxytocic pharmaceuticals sector is experiencing rivalry due to the variety of products supplied by companies related to oxytocic medications to gain market share. The unfavorable side effects of oxytocic drugs that produce excessive postpartum bleeding due to hemorrhage are the main factors preventing the oxytocic pharmaceutical sector from expanding.
Through license agreements, advancements in more recent oxytocic medications may promote sales. The demand for oxytocin pharmaceuticals may benefit from increased usage of antepartum oxytocin injection to stimulate uterine contractions.
| Attribute | Details |
|---|---|
| Oxytocic Pharmaceuticals Market CAGR (2023 to 2033) | 7.8% |
| Oxytocic Pharmaceuticals Market HCAGR (2018 to 2022) | 6% |
| Oxytocic Pharmaceuticals Market Size - 2023 | USD 114.58 million |
| Oxytocic Pharmaceuticals Market Size - 2033 | USD 242.83 million |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Between 2018 and 2022, the oxytocic pharmaceuticals industry captured a 6% CAGR, and it is anticipated that this pattern may hold from 2023 to 2033. Due to growing knowledge of the advantages of oxytocic medications in promoting labor and reducing postpartum hemorrhage, the market saw an increase in demand from 2018 to 2022. Raising birth rates in developing nations and improvements in healthcare facilities aided market expansion.
From 2023 to 2033, the market is expected to continue growing steadily. The market is anticipated to develop due to increased attention paid to maternal health, the rising occurrence of difficulties during childbirth, and the rise in government programs to upgrade healthcare facilities.
The efficacy and safety of oxytocic medications are projected to be improved by technological developments in drug formulations and delivery methods, leading to a rise in their use.
Overall, the market for oxytocic pharmaceuticals is anticipated to expand throughout the forecast period due to rising awareness, rising birth rates, and developments in the infrastructure and technology of the healthcare industry.
Brand names like Pitocin are used to advertise synthetic oxytocin. Artificial medications include derivatives of synthetic oxytocin. In today's market, oxytocin pills and injectables are easily accessible. The initial dose should be 0.5–1 mU/min (equivalent to 3-6 ml of the diluted Oxytocic solution per hour) when considering induction or stimulation of labor.
Oxytocic agents are drugs that stimulate uterine activity. They are used to induce labor, increase contractions, reduce the risk of postpartum hemorrhage right after delivery, and release fetal contents during incomplete abortions. To prevent the development of uterine atony, endogenous oxytocic drugs are also frequently given following C-sections.
Oxytocic drugs are administered intravenously or intramuscularly to treat postpartum hemorrhage, labor induction, and incomplete or unavoidable abortion. As a result of the increasing adoption of oxytocic pharmaceuticals, the market is expanding, adding to the industry outlook.
Principal Consultant
Companies functioning in the global oxytocic pharmaceuticals industry can reap more considerable market revenue from untapped markets in Asia and Africa. Here, the prevalence of postpartum hemorrhage is higher than in other regions.
Imparting awareness about pregnancy among the women in these regions can help create market opportunities for existing as well as new entrants in the global oxytocic medicines market.
The stringent regulatory structure that controls the manufacture and distribution of these medications is the primary constraint. The development of novel oxytocic medicines needs to be improved by the strict regulations and approval procedures established by regulatory agencies.
Smaller pharmaceutical companies have financial obstacles due to the high cost of these drugs' development, manufacture, and marketing, which further restrains market growth for oxytocic pharmaceuticals.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In the upcoming years, the North American oxytocic medicines market is anticipated to expand steadily. Oxytocic medications are frequently used to initiate or speed up labor during childbirth as well as to prevent or manage postpartum hemorrhage. The rising occurrence of difficulties during work and the increasing demand for secure, efficient drugs in obstetrics are driving the market's expansion.
The market expansion is further fueled by the increased emphasis on enhancing maternal healthcare and the accessibility of cutting-edge oxytocic medications. To some extent, nevertheless, market expansion may be hampered by strict rules and expensive oxytocic drugs.
In the future, there may be a significant expansion in the Asia Pacific oxytocic medicines industry. Oxytocic medications are essential for accelerating labor and reducing postpartum hemorrhage. The growing emphasis on enhancing maternal healthcare and lowering maternal death rates is the main factor accelerating the market.
The market is expanding as a result of population growth, increased public awareness of the value of safe delivery techniques, and improvements in the healthcare system. However, issues including strict regulatory guidelines and restricted access to high-quality healthcare in some rural areas may impede the market expansion to some extent.
Due to the increased incidence of pregnancy problems and growing awareness of the importance of safe maternal healthcare, the market for oxytocic medications in Europe is now seeing a considerable increase in demand. Oxytocic medications, frequently used to hasten or speed up labor and treat postpartum hemorrhage, are becoming more widely used.
The availability of cutting-edge oxytocic medicines and improvements in medical technology are also boosting market expansion. However, the high cost of these pharmaceuticals and strict regulatory requirements are obstacles to the market's progress. Despite these obstacles, producers should have attractive prospects in the European oxytocic medicines market in the years to come.
| Segment | Postpartum Haemorrhage |
|---|---|
| Segment Share | 75% |
The postpartum hemorrhage category holds more than 75% of the global oxytocic medicines market. By 2026, it is anticipated to increase its market share by more than 200 BPS. During the forecast period, the postpartum hemorrhage segment is expected to develop rapidly year over year and hold its position as the dominating segment.
The issue of postpartum bleeding is driven by the rise in births through labor induction. Pre-eclampsia is one occasion where extending the pregnancy could be harmful to the mother. Other times, women may feel uncomfortable, sore, or exhausted. When this happens, convenience over medical needs is the primary motivation for inducing labor. Postpartum hemorrhage risk rises with labor induction.
The World Health Organization states that labor induction rates are lower in developing nations but are substantially higher in developed countries, which has a favorable effect on the postpartum hemorrhage sector. The aging of mothers is another aspect predicted to contribute to the postpartum hemorrhage segment's revenue growth. After giving birth, heavy bleeding is more common in older and smoking women.
In virtually every region of the world, the rate of pregnancies after a particular age has increased, spurring growth in the postpartum hemorrhage section of the worldwide oxytocic drugs market.
| Segment | Hospital |
|---|---|
| Segment Share | 67% |
With the leading market share of 67% in the end-use category of oxytocic medicines globally in 2020, the hospital segment is projected to attract more attention. Oxytocin is frequently utilized in prenatal medicine, although a high dose can have significant adverse consequences. Pregnant women who have labor pain and breastfeeding mothers both need perinatal medications. Oxytocin is administered intravenously in a hospital under medical supervision to start labor or amplify contractions.
Hospitals also utilize oxytocic medications for a variety of causes in obstetrics and obstetric anesthesia. As opposed to natural oxytocin, synthetic oxytocin is a medication that is frequently used. A high dose of synthetic oxytocin may also have several undesirable side effects on patients.
Compared to other clinics, hospitals tend to administer oxytocin more frequently. The increased availability of medications at hospital pharmacies is another crucial aspect driving the market's expansion.
The oxytocic pharmaceuticals market is characterized by fierce rivalry among several significant competitors. This competitive landscape examines both international and domestic firms.
These companies are employing a variety of measures to maintain their market shares, including mergers, acquisitions, collaborations, and new releases. Such approaches allow them to keep ahead of the competition and propel the oxytocin medicines sector forward.
Key Oxytocic Pharmaceuticals Manufacturers
Recent Breakthroughs and Developments
| Company | Tonix Pharmaceuticals |
|---|---|
| Strategy | Tonix Pharmaceuticals granted the United States patent for intranasal oxytocin painkillers with magnesium-containing formulations |
| Details | Tonix Pharmaceuticals was granted a United States patent in August 2022 for its intranasal Oxytocin (TNX-1900) painkiller. Intranasal magnesium-containing oxytocin formulations were claimed in the patent, named ‘Magnesium-Containing Oxytocin Formulations and Methods of Use,’ as well as methods and compositions for relieving pain, including those related to migraine headaches. With the probable exception of patent term extensions, this patent is anticipated to give Tonix in the United States market exclusivity until January 2036. |
| Company | Drugs Controller General of India (DCGI) |
|---|---|
| Strategy | India allows the import of Oxytocin reference standards for testing |
| Details | After submitting a test license provided by the Drugs Controller General of India (DCGI), the Central Government of India permitted the import of oxytocin reference standards for testing and analysis in May 2022. |
| Company | Zentalis Pharmaceuticals |
|---|---|
| Strategy | Zentalis Pharmaceuticals announce USD 25 million share sale to Pfizer |
| Details | Zentalis Pharmaceuticals announced in April 2022 that it has agreed to sell 953,834 of its common shares to Pfizer for USD 25.0 million (the Transaction). Pfizer received and purchased the common shares in a registered direct offering without the use of an underwriter or placement agent. |
The market is pegged to achieve USD 242.83 million by 2033.
The growth potential of the oxytocic pharmaceuticals market is 7.8% CAGR through 2033.
Manufacturers need to tackle financial barriers and regulatory hurdles for their long-term market presence.
Government initiatives are providing opportunities for key players.
App Pharmaceuticals LLC, Teva Parenteral Medicines Inc., and Abbott Laboratories are key oxytocic pharmaceuticals market players.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 5.1. Abortion Induced Incomplete 5.2. Inevitable Abortion 5.3. Post-partum Haemorrhage 5.4. Labour Induction 5.5. Labour Arrest 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Intravenous Infusion/Injection 6.2. Intramuscular Injection 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Source of Origin 7.1. Natural Oxytocin 7.2. Synthetic Oxytocin Derivative 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 8.1. Hospitals 8.2. Maternity Clinics 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. South Asia and Pacific 9.6. East Asia 9.7. Middle East and Africa 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Pfizer, Inc. 19.2. Fresenius Kabi AG 19.3. Novartis AG 19.4. Cardinal Health 19.5. Ferring Pharmaceuticals B.V. 19.6. Par Sterile Products, LLC (Endo International plc) 19.7. Teva Pharmaceutical Industries 19.8. Biofutura 19.9. Baxter Healthcare 19.10. Hikma Pharmaceuticals PLC 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Oxytocic Pharmaceuticals Market
